Insiders Neurogene Inc.

Equities

NGNE

US64135M1053

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
32.9 ^USD	-3.06%		-2.58%	+69.76%

May. 07	Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting	CI
Apr. 29	Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target	MT

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Neurogene Inc. Appoints Donna Cochener as Senior Vice President, General Counsel	Feb. 21	CI
Neurogene Inc. Appoints Julie Jordan as Chief Medical Officer	Jan. 17	CI
Neurogene Names Julie Jordan as Chief Medical Officer	Jan. 16	MT
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	Jan. 16	CI
Neoleukin Therapeutics, Inc. Appoints Sean Smith as Interim Chief Financial Officer	23-04-03	CI
Neoleukin Therapeutics, Inc. Appoints Donna M. Cochener as the Interim Chief Executive Officer	23-04-03	CI
Neoleukin Therapeutics, Inc. Announces Board Changes	23-03-10	CI
Neoleukin Therapeutics Weighs Potential Sale, Plans to Cut Workforce by 70%; CEO Drachman to Leave	23-03-08	MT
Neoleukin Therapeutics, Inc. Announces Stepping Down of Jonathan Drachman, M.D. as Chief Executive Officer	23-03-08	CI
Neoleukin Therapeutics, Inc. Appoints Donna M. Cochener as General Counsel, Senior Vice President Legal	22-03-15	CI
Neoleukin Therapeutics, Inc. Announces Management Changes	22-03-11	CI
Neoleukin Therapeutics Inc. Announces Executive Changes	22-03-01	CI
Neoleukin Therapeutics, Inc. Announces Resignation of Robert Ho as Chief Financial Officer, Effective March 1, 2022	22-02-15	CI
Neoleukin Therapeutics, Inc. Announces Resignation of Robert Ho as Corporate Secretary, Effective March 1, 2022	22-02-15	CI
Neoleukin Therapeutics, Inc. Announces Resignation of Holly Vance as General Counsel and Corporate Secretary	21-11-19	CI
Insider Trends: 90-Day Buying Trend Prolonged with Insider Purchase of Neoleukin Therapeutics Stock	21-06-07	MT
Neoleukin Therapeutics Announces Appointment of Priti Patel as Chief Medical Officer	21-05-03	CI
Insider Trends: Insider Acquisition Interrupts 90-Day Trend of Sales at Neoleukin Therapeutics	20-12-23	MT
Neoleukin Therapeutics Appoints Holly K. Vance as General Counsel	20-10-20	CI
Neoleukin Therapeutics, Inc. Announces Appointment of Martin Babler to Board of Directors	20-09-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders Neurogene Inc.

Equities

NGNE

US64135M1053

Insiders

Filters